

# Role of the Federal Government in Advancing DM Science and Care – the FDA

## 2014 Myotonic Dystrophy Foundation Annual Conference, Washington DC

*Ronald Farkas, M.D., Ph.D.*

*Clinical Team Leader, Division of Neurology Products*

*Center for Drug Evaluation and Research (CDER)*

*Food and Drug Administration (FDA)*



# What does FDA do?

- Assures the safety, effectiveness and quality of drugs, medical devices, food, cosmetics and products that emit radiation...
- Mainly by reviewing information collected and submitted by industry, academia, and others

# What FDA doesn't do with drugs

- Make or have access to experimental drugs
  - Drugs are made and owned by industry and academia
- Conduct animal or human studies
  - FDA requires information before drugs can be studied or marketed; industry and academia conduct the studies
- Set or limit price
- Regulate “Practice of medicine”
  - e.g. an approved drug *can* be used, but FDA has only indirect role in decisions about *if or when* it is used
- Require new drugs to be better than old drugs



# FDA Organization

- Part of Department of Health and Human Services
  - Sister agencies include NIH, CDC, CMS and 8 others
- Centers:
  - Drugs (CDER)
  - Biologics (CBER)
  - Devices and radiology (CDRH)
  - Food (CFSAN)
  - Tobacco (CTR)
  - Veterinary medicine (CVM)
  - Toxicological Research (NCTR)

# Key Laws

1906 FDA created to prevent adulterated food and drugs

1938 Drugs required to be safe

1962 Drugs required to be effective

**Need to show benefit before FDA can consider “risks vs. benefits”**

# Drug Development Steps and FDA

**“test tube” studies**



**animal studies**



**human studies**

**Phase 1 → Phase 3**



**Marketing application to FDA**



**post-marketing trials and surveillance-  
mainly for safety**

**8 months**



# Drug Development Steps and FDA

**“test tube”  
studies**



**animal studies**



**human studies  
“IND application”**



**Marketing  
application to FDA**

**Before an experimental drug is given to people, FDA has to review the plan and conclude it doesn't present “unreasonable risk”**

**IND = investigational new drug**

# Unreasonable Risk

- Depends on the disease; if life-threatening *or* debilitating, some amount of life-threatening risk may be reasonable
- Importantly, to support human studies developers *required* to study amount of risk, and reduce to degree that's *reasonable*
  - e.g. if a drug injures kidneys in animals, choose dose based on that for humans, and use specialized tests to detect kidney injury early

# What Kind of Study or Use?

**“test tube”  
studies**



**animal studies**



**human studies  
“IND application”**



**Marketing  
application to FDA**

FDA can't allow use in patients or uncontrolled studies if will impede trials capable of showing if the drug works

...studies are rarely stopped by FDA for a number of other reasons, like faulty design that won't lead to useful information

# Expanded Access

- Drug used to treat patients
- The law allows, and FDA encourages, when won't impede studies needed to show if a drug works or not, and the disease, risks, and possible benefits fit
- Evidence that a drug works almost never provided by use in treatment setting

# How do you know if a drug works?

- If the drug effect is large, immediate and clearly different from what could happen to untreated patients, efficacy can be shown fairly easily – like for drugs that produce surgical anesthesia
- But drugs for most diseases aren't likely to have such clear efficacy
- FDA is eager to approve drugs with small benefits – but that benefit needs to be reliably shown

# Historical Controls in Efficacy Studies

- Treat all patients with the experimental drug and compare to how they did in the past, or to other patients in the past
- The major problem with this approach is called “bias” – as used in science, it includes not only believing a drug works only because you want it to work (although *is* a major concern), but also accidental and invisible differences between present and past that mislead

# Historical Controls

- Many sources of accidental bias
  - Supportive care for patients in a study more intensive than supportive care outside, so patients often do better in study
  - Supportive care today often better than yesterday, sometimes much better
  - Patients doing worse than average more likely to leave the study – the remaining patients are “better than average” even if the drug didn’t work
  - and many more...

# “Drug vs. Drug” Trials

- *Can* sometimes use to support FDA approval, but often not possible or practical
- Best when a new drug might be more effective than a drug that is already approved
  - but still risky for drug developers if new drug might not be better than approved drug
  - And bigger study needed to show new drug beats old drug compared to showing new drug beats placebo
- And doesn't actually get rid of concern to some that patients don't get immediate access to new drug

# Placebo-Controlled Trials

- Not without cost or risk, but usually the best bet in a world made of costs and risks
- Use when drug *not* obviously effective
  - Even if drug works, the difference between drug- and placebo patients will be so small when detected that patients still can't tell who got drug and who got placebo
- Much of the objection to placebo based on belief new drug likely is effective; hard experience tells us most are not

# Rare Diseases/Orphan Drugs

- Diseases that affect <200,000 persons in the US
- Orphan Drug Act passed in 1983
  - does not lower requirement for showing drug works
- FDA is required [and very willing] to exercise its scientific judgment to determine the kind and quantity of data and information an applicant is required to provide for a particular drug to meet the statutory standards



Thank you

Questions?